Cannabis now falls under Health Canadaregulations, like any other consumable product. That means more business for lab-testing companies because growers, and producers of capsules, oils and other cannabis-based products, must have their products tested by licensed labs to determine potency and the presence of heavy metals, pesticides, yeast and mould.

A couple of dozen independent labs across Canada are licensed to test cannabis products. But there has been a trend lately where bigger players in the medical marijuana industry are not content to merely contract out their testing and research. They have been acquiring testing and research labs to bring that expertise in-house.

Investors have been watching the marijuana industry as a hotbed of activity for months now, and 2019 has been extremely good to the top players in the fast-growing cannabis space. For those willing to buy individual marijuana stocks, a rising number of companies available to U.S. investors on major stock exchanges have offered new opportunities.

Recreational marijuana use became legal across Canada last October, sparking a wave of new cannabis-based businesses. The hospitality industry took note, and now you can tour a giant weed factory or get high while helicoptering over coastal mountains in British Columbia.

1. Butiq Escapes, British Columbia

This luxury travel company will take you and your friends to a remote mountain wilderness via helicopter for a once-in-a-lifetime glamping experience. They’ll fly in a chef, DJ or yoga instructor—whatever you want—and supply a curated assortment of the best marijuana strains and cannabis-infused goodies from across Canada. Expect to drop at least 10 grand.

Canopy Growth (TSX:WEED)(NYSE:CGC) has been on the rise again. Last week, the stock closed at over $67 — the last time it did that was back in late January. The last time the share price closed at over $70 was back in October, right around legalization and before pot stocks took a big hit.

A Winnipeg city councillor says it's time to move large scale medical marijuana grow ops out of residential neighbourhoods and into industrial areas.

Health Canada says people with a registered certificate to grow medical pot in their homes for personal use can possess up to 150 dried grams or 300 fresh grams.

There can also be up to four registrations in place for production at one location.

Coun. Ross Eadie says he's been receiving complaints about suspected medical grow ops causing odour and noise problems in two neighbourhoods. 

“A person’s right to medical cannabis does not trump people’s right to live comfortably next door,” says Eadie

In case you haven't noticed, big things are happening with the legal marijuana industry. It's already growing at an impressive pace, and excitement surrounding the legal pot industry really took off following the legalization of recreational marijuana in Canada in October. Eventually, Wall Street is looking for the cannabis industry to generate $50 billion to $75 billion in sales by the end of the next decade.

U.S. medical cannabis producer Columbia Care begins trading on Canada’s NEO Exchange

As the cannabis industry finally takes off after nearly a century of prohibition, investors have neglected to ask themselves a central question. It might seem too obvious to even ask, but as you’ll see in this report, that is not the case at all. That question is, who should cannabis be marketed to?

I’m going to make the case here that the big and familiar players in the cannabis industry are all ignoring this critical question. I’m going to show you how one small and extremely undervalued ultra-premium focused cannabis firm is one of the very few answering it correctly.

Zenabis Global Inc. (TSXV: ZENA)("Zenabis" or the "Company") is pleased to announce that it has entered into a binding term sheet for a three-year supply arrangement with leading German pharmaceutical research company Farmako GmbH ("Farmako") for: (1) the supply of biosynthetically produced pure CBD isolate oil (99.9%) from Farmako to Zenabis for sale in Canada; and (2) the supply of European Union Good Manufacturing Practices ("EU GMP") certified cannabis cultivated in Zenabis' indoor facilities in Canada for sale by Farmako to the German medical market.

The upstart NEO Exchange scored its first billion-dollar corporate listing today with U.S. medical cannabis producer Columbia Care.

The New-York based cultivator, manufacturer and dispensary operator made its debut with a market capitalization of more than $2-billion.

The stock exchange said Monday the multi-state operator, with a presence in roughly 15 states, is the first company to list on the NEO with an enterprise value of over $1 billion.

"This is an exciting time to be partnering with a leader in the U.S. cannabis sector as it moves into its next phase and looks to raise capital on the North American public markets," NEO chief executive Jos Schmitt said in a statement.

Columbia Care trades under the symbol CCHW.